GTx Continues Phase III For Toremifene 20 Mg With Goal Of 2009 NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Bar is lower for meeting primary efficacy endpoint at trial’s end than for interim data review, firm tells “The Pink Sheet” DAILY.